Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.7
3.2
Journals
Life
Special Issues
Advances in Diagnosis and Treatment of Hypertrophic Cardiomyopathy
share announcement

Advances in Diagnosis and Treatment of Hypertrophic Cardiomyopathy

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".

Deadline for manuscript submissions: closed (30 June 2022) | Viewed by 2065

Special Issue Editor

Dr. Attila Frigy

E-Mail
Guest Editor
Department of Internal Medicine IV, University of Medicine, Pharmacy, Science and Technology, “George Emil Palade” of Targu Mures, 540139 Târgu Mureș, Romania
Interests: hypertrophic cardiomyopathy; cardiac imaging; echocardiography; MRI; computed tomography; invasive imaging; diagnosis; therapy; risk stratification; prognosis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

It is my great pleasure to be Guest Editor of the Special Issue dealing with the topic of Diagnosis and Treatment of Hypertrophic Cardiomyopathy (HCM). Despite the significant progress noted in the diagnosis and management of HCM, there is still room for good quality research, for new and sound scientific achievements. The aim of the Special Issue is to gather articles dealing with diagnostic and therapeutic issues related to HCM, sharing new, clinically relevant information about the role and value of diverse imaging or other types of diagnostic modalities and therapeutical methods in the management of the disease. You are cordially invited to send your manuscripts containing your new research results or your review concerning a hot topic in the field of HCM diagnosis and therapy. Also, case reports reflecting important or difficult problems of clinical practice are welcome.

Dr. Attila Frigy
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hypertrophic cardiomyopathy
  • cardiac imaging
  • echocardiography
  • MRI
  • diagnosis
  • pharmacotherapy
  • invasive therapy
  • risk stratification
  • prognosis

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 921 KiB  
Article
Association of NT-proBNP and hs-cTnT with Imaging Markers of Diastolic Dysfunction and Focal Myocardial Fibrosis in Hypertrophic Cardiomyopathy
by Céleste Chevalier, Miriam Wendner, Anna Suling, Ersin Cavus, Kai Muellerleile, Gunnar Lund, Paulus Kirchhof and Monica Patten
Life 2022, 12(8), 1241; https://doi.org/10.3390/life12081241 - 16 Aug 2022
Cited by 3 | Viewed by 1658
Abstract
Serum biomarkers such as N-terminal prohormone of the brain natriuretic peptide (NT-proBNP) and cardiac troponins are elevated in patients with hypertrophic cardiomyopathy (HCM). At present, it is not clear if these markers are associated with distinct clinical alterations in HCM, such as left [...] Read more.
Serum biomarkers such as N-terminal prohormone of the brain natriuretic peptide (NT-proBNP) and cardiac troponins are elevated in patients with hypertrophic cardiomyopathy (HCM). At present, it is not clear if these markers are associated with distinct clinical alterations in HCM, such as left ventricular hypertrophy, outflow tract obstruction, myocardial fibrosis and/or diastolic dysfunction (DD), which are associated with adverse cardiovascular outcome. Here we evaluate the association of NT-proBNP and high sensitivity cardiac troponin T (hs-cTnT) to a variety of cardiac imaging parameters in HCM patients in a multivariable regression analysis. This retrospective cross-sectional study included 366 HCM patients who underwent transthoracic echocardiography (TTE), 218 of whom also obtained cardiovascular magnetic resonance (CMR) to assess focal myocardial fibrosis by LGE. Multivariable regression analyses revealed the strongest association of the DD parameters E/E′ mean and E/E′ septal with NT-proBNP (b = 0.06, 95%-CI [0.05–0.07], p < 0.001, R2 = 0.28; b = 0.08, 95%-CI [0.06–0.1], p < 0.001, R2 = 0.25) and LGE size showed the strongest association with hs-cTnT (b = 0.20, 95%-CI [0.15–0.24], p < 0.001, R2 = 0.28). This study indicates that NT-proBNP and hs-cTnT are associated with structural and functional alterations in HCM. NT-proBNP is a stronger predictor for DD, while hs-cTnT is associated with the extent of focal myocardial fibrosis. Both biomarkers might be useful in the diagnostic procedure in addition to imaging parameters. Full article
(This article belongs to the Special Issue Advances in Diagnosis and Treatment of Hypertrophic Cardiomyopathy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop